ZA200807263B - Novel heteroaryl-substituted arylaminopyrldine derivatives as MEK inhibitors - Google Patents

Novel heteroaryl-substituted arylaminopyrldine derivatives as MEK inhibitors

Info

Publication number
ZA200807263B
ZA200807263B ZA200807263A ZA200807263A ZA200807263B ZA 200807263 B ZA200807263 B ZA 200807263B ZA 200807263 A ZA200807263 A ZA 200807263A ZA 200807263 A ZA200807263 A ZA 200807263A ZA 200807263 B ZA200807263 B ZA 200807263B
Authority
ZA
South Africa
Prior art keywords
arylaminopyrldine
derivatives
substituted
mek inhibitors
novel heteroaryl
Prior art date
Application number
ZA200807263A
Other languages
English (en)
Inventor
Goutopoulos Andreas
Jr Benny C Askew
Chen Xiaoling
Karra Srinivasa
Yu Henry
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of ZA200807263B publication Critical patent/ZA200807263B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA200807263A 2006-04-19 2007-04-18 Novel heteroaryl-substituted arylaminopyrldine derivatives as MEK inhibitors ZA200807263B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79307306P 2006-04-19 2006-04-19

Publications (1)

Publication Number Publication Date
ZA200807263B true ZA200807263B (en) 2009-11-25

Family

ID=38357968

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200807263A ZA200807263B (en) 2006-04-19 2007-04-18 Novel heteroaryl-substituted arylaminopyrldine derivatives as MEK inhibitors

Country Status (14)

Country Link
US (1) US8076486B2 (enExample)
EP (1) EP2013180A1 (enExample)
JP (1) JP5525812B2 (enExample)
KR (1) KR20090005195A (enExample)
CN (2) CN103121996B (enExample)
AR (1) AR060807A1 (enExample)
AU (1) AU2007240860A1 (enExample)
BR (1) BRPI0711625A2 (enExample)
CA (1) CA2644425A1 (enExample)
EA (1) EA200802050A1 (enExample)
IL (1) IL194546A0 (enExample)
MX (1) MX2008013308A (enExample)
WO (1) WO2007123936A1 (enExample)
ZA (1) ZA200807263B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007123939A2 (en) * 2006-04-19 2007-11-01 Laboratoires Serono S.A. Novel arylamino n-heteraryls as mek inhibitors
EP2231636B1 (en) * 2007-12-07 2011-09-14 Novartis AG Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
CA2789696C (en) 2010-02-25 2017-11-07 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
WO2016142894A1 (en) * 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
MA42145B1 (fr) 2015-05-20 2020-05-29 Amgen Inc Triazoles agonistes du récepteur apj
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US11186554B2 (en) 2017-05-03 2021-11-30 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
WO2019040380A1 (en) 2017-08-21 2019-02-28 Vivace Therapeutics, Inc. BENZOSULFONYL COMPOUNDS
WO2019089335A1 (en) 2017-11-03 2019-05-09 Amgen Inc. Fused triazole agonists of the apj receptor
WO2019113236A1 (en) 2017-12-06 2019-06-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
EP3720438B1 (en) * 2017-12-07 2023-08-30 Amplyx Pharmaceuticals, Inc. Heterocycle substituted pyridine derivative antifungal agents
CN110317190A (zh) * 2018-03-28 2019-10-11 首都医科大学 一种三唑-羧酸酯类衍生物在医药领域的应用
EP3788037A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CA3100503A1 (en) 2018-05-16 2019-11-21 Vivace Therapeutics, Inc. Oxadiazole compounds
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
CN115279368B (zh) * 2019-11-20 2024-05-24 维瓦斯治疗公司 杂芳基化合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JP2024521788A (ja) 2021-05-27 2024-06-04 ミラティ セラピューティクス, インコーポレイテッド 併用療法
CN118973580A (zh) 2022-04-08 2024-11-15 米拉蒂治疗股份有限公司 包含sos1抑制剂和mek抑制剂的组合疗法
WO2025054260A1 (en) * 2023-09-07 2025-03-13 Kinnate Biopharma Inc. Inhibitors of mek kinase
EP4788839A1 (en) 2023-10-03 2026-08-12 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002534515A (ja) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー 1−複素環置換されたジアリールアミン
GB2373245A (en) * 2001-03-12 2002-09-18 Bayer Ag Pyridinyl pyrazoles and their use for the treatment of COPD
BR0314195A (pt) * 2002-09-10 2005-07-26 Pharmacia Italia Spa Derivados de piridina substituìda como agentes antitumorais
AU2003293376A1 (en) * 2002-12-10 2004-06-30 Imclone Systems Incorporated Anti-angiogenic compounds and their use in cancer treatment
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
AU2004229392A1 (en) * 2003-04-09 2004-10-28 Exelixis, Inc. Tie-2 modulators and methods of use
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20090048301A1 (en) 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
ES2444866T3 (es) * 2004-10-20 2014-02-27 Merck Serono Sa Derivados de 3-arilamino piridina

Also Published As

Publication number Publication date
MX2008013308A (es) 2008-10-27
CN101426766B (zh) 2014-03-26
EA200802050A1 (ru) 2009-04-28
CN103121996B (zh) 2015-10-21
US8076486B2 (en) 2011-12-13
AR060807A1 (es) 2008-07-16
CN103121996A (zh) 2013-05-29
EP2013180A1 (en) 2009-01-14
AU2007240860A1 (en) 2007-11-01
US20070287737A1 (en) 2007-12-13
JP5525812B2 (ja) 2014-06-18
CN101426766A (zh) 2009-05-06
KR20090005195A (ko) 2009-01-12
WO2007123936A1 (en) 2007-11-01
BRPI0711625A2 (pt) 2011-12-06
HK1127354A1 (en) 2009-09-25
CA2644425A1 (en) 2007-11-01
IL194546A0 (en) 2009-08-03
JP2009534386A (ja) 2009-09-24

Similar Documents

Publication Publication Date Title
IL192603A0 (en) Thieno-pyridine derivatives as mek inhibitors
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
IL192634A0 (en) Thiazoles as 11 beta-hsd1 inhibitors
ZA200904108B (en) Pyrido-pyrazine derivatives useful as herbicidal compounds
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
PL2383271T3 (pl) Aminochinolony jako inhibitory GSK-3
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
IL200047A0 (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
PL2220070T3 (pl) Pochodne 2-benzylopirydazynonowe jako inhibitory kinazy met
ZA200809800B (en) 2-Thioxanthine derivatives acting as Mpo-inhibitors
IL195158A0 (en) Novel heterocyclic compounds
IL198014A0 (en) Heterocyclic derived metalloprotease inhibitors
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL187575A0 (en) Benzofuranyl derivatives as 5-ht6-receptor inhibitors
GB0622472D0 (en) Novel heterocyclic derivatives
IL196807A0 (en) Inhibitors for glyt-1
ZA200905235B (en) Pyrazole derivatives as 11-beta-hsd1 inhibitors
ZA200710338B (en) Oxydiazole derivatives as DGAT inhibitors
GB0614154D0 (en) Novel Pyriazine Derivatives
HK1156319A (en) Heterocyclic derivatives as hdac inhibitors
ZA200809385B (en) Novel heterocyclic compounds
GB0618472D0 (en) Prior art tracker
GB0707499D0 (en) Novel inhibitors
GB0707498D0 (en) Novel inhibitors